29 citations
,
March 2023 in “The Journal of Dermatology” In this study, 16% of patients on dupilumab for atopic dermatitis experienced mild cutaneous adverse events, most commonly facial redness and psoriasis, leading to discontinuation in about 3% of cases.
26 citations
,
October 2018 in “Clinical & Translational Oncology” This review outlines dermatological toxicities associated with targeted cancer therapies and immunotherapies, emphasizing the need for collaborative management by oncologists and dermatologists but reports no new clinical findings.
21 citations
,
November 2018 in “Journal of the European Academy of Dermatology and Venereology” In this study, encorafenib combined with binimetinib was well tolerated in melanoma patients, resulting in relatively few cutaneous adverse events compared to other BRAF and MEK inhibitors.
7 citations
,
November 2021 in “Anais Brasileiros de Dermatologia” This retrospective study found a variety of dermatological adverse events associated with antineoplastic treatments, often leading to changes or suspension of cancer therapies in affected patients.
2 citations
,
December 2015 in “DOAJ (DOAJ: Directory of Open Access Journals)” This study reports that targeted anticancer therapies frequently cause skin-related side effects, which may impact patient adherence and quality of life, but these effects are positively correlated with treatment response.